Ohio State's Dorothy M. Davis Heart and Lung Research Institute

Visit the DHLRI Website

Our Vision:

• Bring together the world's best scientific minds in an open environment that fosters and enhances innovative, creative inquiry.
• Encourage the intermingling of basic and clinical scientists from diverse specialties.
• Create research projects that look at heart and lung health issues not just from one or two sides, but from all viewpoints.
• Focus on outcomes that advance patient care, knowledge and our ability to create new knowledge.

2010 Accomplishments

• New DHLRI Director Peter Mohler, PhD, will lead the DHLRI into the next phase of growth. This growth will include foundational growth in faculty recruitment and increased NIH funding. In addition, DHLRI will focus on establishing a translational fellowship program with an emphasis on personalized medicine. 
• There are 200 active clinical trials associated with DHLRI.
• DHLRI was awarded an estimated $25.5 million in extramural funding.
• The DHLRI-based Antioxidants & Redox Signaling journal received a 7.581 impact factor by Thomson Reuters in 2010.
• Dr. Sanjay Rajagopalan and his research team are looking at more than just the foods we eat, but the air we breathe to better understand diabetes.  The research may reveal that pollution is a factor in the onset of diabetes.
• DHLRI researchers and clinicians found that “pretreating” adult stem cells with an anti-angina drug allows them to better adapt to the harsh environment of their transplantation site and possibly aid the regeneration of heart muscle. Scientists are studying whether transplanted cells eliminate or slow tissue deterioration that would lead to heart failure.
• Sleep medicine and cardiology researchers at the DHLRI are the first to evaluate the impact of obstructive sleep apnea on patients admitted to the hospital with heart failure. The results showed that early identification and treatment of obstructive sleep apnea in hospitalized patients with acutely decompensated heart failure improves heart function.
• Dr. Subha Raman was named OSU’s Early Career Innovator of the Year for 2010. Dr Raman has leveraged her background in electrical engineering and her expertise in cardiac imaging to build an extraordinarily exciting and impactful commercialization portfolio. She has focused her commercialization efforts in two areas: First, the detection of vulnerable plaque through noninvasive, noncontrast magnetic resonance for which there is a patent pending, and second, more accurate diagnosis of cardiovascular disease through innovations in stress testing, for which there is also a patent pending. She and her co-investigators have formed a university technology start-up company (EXCMR Ltd.) to commercialize the treadmill CMR technology.